Survival of 156 patients after disease progression. The median follow-up period after progression was 77 months (range 6 - 136). (A) Survival of 156 patients after disease progression. The median follow-up period after progression was 77 months (range 6-136). (B) Survival after disease progression according to age at time of relapse/refractory disease. (C) Survival after disease progression according to duration of REM1 duration. Mth, months; yr, year; mOS, median overall survival.